About Exopharm

Exopharm Pty Ltd is a privately held regenerative medicines company focused on bringing extracellular vesicle/exosome therapy to patients and medical professionals to solve important unmet medical needs.

Vesicles manufactured using Exopharm’s LEAP technology are called exomeres.
Exomere therapy is a completely new class of cell free drug, using natural exomeres purified from sources such as blood plasma and adult stem cell secretome.
Exopharm has patented LEAP, a unique proprietary technology to isolate and purify intact exomeres in large-scale and at low cost.

As the rich and powerful regenerative biology of exosomes/extracellular vesicles is increasingly understood, the time has come to turn this knowledge into first solutions for human health through accelerated progress from pharma-grade manufacturing and preclinical testing to clinical trials in selected indications.

Exopharm, its team and our investors are focused on translating cutting-edge science to bring answers to patients with conditions such as tendinopathy, age-related eye disease, fibrosis, joint disease, degeneration and ageing.

Exopharm is partnering with thought-leaders in the field and is building strong relationships with clinicians in selected therapeutic areas.

Our Team.

Dr. Ian Dixon

CEO

linkedin

Dr. Gregor Lichtfuss

COO

twitter linkedin

Dr. Jim Palmer

Drug Development

linkedin